Harnessing the power of memory-like NK cells to fight cancer
Clinical and Experimental Immunology · 2023
DOI: 10.1093/cei/uxad030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2023. Verfasst von Yun Yan Foo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Development, CELLAAX Sdn Bhd, Block D & E, No. 3, Jalan Tasik, Mines Wellness City, Seri Kembangan, 43300 Selangor, Malays…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Natural killer (NK) cells possess the innate ability to eliminate cancerous cells effectively. Their crucial role in immunosurveillance has been widely recognized and exploited for therapeutic intervention. Despite the fast-acting nature of NK cells, NK adoptive cell transfer lacks favorable response in some patients. Patient NK cells often display diminished phenotype in preventing cancer progression resulting in poor prognosis. Tumor microenvironment plays a significant role in causing the downfall of NK cells in patients. The release of inhibitory factors by tumor microenvironment hinders normal function of NK cells against tumor. To overcome this challenge, therapeutic strategies such as cytokine stimulation and genetic manipulation are being investigated to improve NK tumor-killing capacity. One of the promising approaches includes generation of more competent NK cells via ex vivo cytokines activation and proliferation. Cytokine-induced ML-NK demonstrated phenotypic alterations such as enhanced expression of activating receptors which help elevate their antitumor response. Previous preclinical studies showed enhanced cytotoxicity and IFNγ production in ML-NK cells compared to normal NK cells against malignant cells. Similar effects are shown in clinical studies in which MK–NK demonstrated encouraging results in treating hematological cancer. However, there is still a lack of in-depth studies using ML-NK in treating different types of tumors and cancers. With convincing preliminary response, this cell-based approach could be used to complement other therapeutic modalities to achieve better clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research and Development, CELLAAX Sdn Bhd, Block D & E, No. 3, Jalan Tasik, Mines Wellness City, Seri Kembangan, 43300 Selangor, Malaysia.
- Beike 23 Century Laboratory, 23 Century International Life Science Centre, Block D & E, No. 3, Jalan Tasik, Mines Wellness City, Seri Kembangan, 43300 Selangor, Malaysia.
ORCID-Profile: Yun Yan Foo
Zitieren
APA
Foo, Y. Y., Tiah, A., & Aung, S. W. (2023). Harnessing the power of memory-like NK cells to fight cancer. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad030
Vancouver
Foo YY, Tiah A, Aung SW. Harnessing the power of memory-like NK cells to fight cancer. Clinical and Experimental Immunology. 2023. doi:10.1093/cei/uxad030
BibTeX
@article{Foo2023,
author = {Foo, Yun Yan and Tiah, Angelina and Aung, Shuh Wen},
title = {Harnessing the power of memory-like NK cells to fight cancer},
journal = {Clinical and Experimental Immunology},
year = {2023},
doi = {10.1093/cei/uxad030}
}
EUVIMED